Hodgkin’s lymphoma and non-Hodgkin’s lymphoma are both cancers of the lymphatic system, but they differ in important ways: the type of abnormal cell involved, how the disease spreads through the body, who it typically affects, and how it responds to treatment. The single most important distinction comes down to what doctors see under a microscope. Hodgkin’s lymphoma contains a specific abnormal cell, called a Reed-Sternberg cell, that non-Hodgkin’s lymphoma does not.
The Cell That Separates the Two
When a pathologist examines a tissue sample from a swollen lymph node, the presence or absence of Reed-Sternberg cells determines which type of lymphoma a person has. These cells are much larger than normal cells and contain two or more nuclei that, under a microscope, look like a pair of owl eyes. They’re actually quite rare in the tumor itself. Only about 1 in every 100 cells in Hodgkin’s lymphoma tissue is a Reed-Sternberg cell, but finding even one is enough to make the diagnosis.
Non-Hodgkin’s lymphoma, by contrast, involves cancerous versions of the immune cells themselves. About 80% of non-Hodgkin’s cases arise from B-cells, the immune cells that produce antibodies. Another 15% come from T-cells, which coordinate immune responses and kill infected cells. This variety in cell origin is one reason non-Hodgkin’s lymphoma is far more complex.
One Disease vs. Dozens
Hodgkin’s lymphoma is relatively straightforward in terms of classification. It falls into two core categories: classical Hodgkin’s lymphoma (which accounts for the vast majority of cases) and nodular lymphocyte-predominant Hodgkin’s lymphoma.
Non-Hodgkin’s lymphoma is more like an umbrella term covering a huge family of related cancers. The National Cancer Institute’s classification system lists over 40 distinct subtypes, each with different behavior, growth rates, and treatment needs. Some are indolent, meaning they grow slowly over years and may not need immediate treatment. Others are aggressive and require urgent intervention. This diversity makes non-Hodgkin’s lymphoma harder to generalize about, because one person’s experience with a slow-growing follicular lymphoma will look nothing like another person’s experience with an aggressive diffuse large B-cell lymphoma.
How Each One Spreads
Hodgkin’s lymphoma tends to spread in an orderly, predictable fashion. It typically moves from one group of lymph nodes to the next neighboring group, following a contiguous path through the lymphatic system. This step-by-step pattern makes it easier to stage and, in many cases, easier to target with radiation.
Non-Hodgkin’s lymphoma is less predictable. It can skip around the body, appearing in lymph node groups that aren’t connected to each other. It’s also more likely to show up outside the lymph nodes entirely. Roughly one-third of non-Hodgkin’s cases originate in extranodal sites, with the stomach, skin, and mouth or throat being the most common locations. Hodgkin’s lymphoma rarely starts outside the lymph nodes.
Who Gets Each Type
Non-Hodgkin’s lymphoma is far more common. An estimated 79,320 new cases will be diagnosed in the United States in 2026, making it about 3.8% of all new cancers. Hodgkin’s lymphoma accounts for roughly 8,000 to 9,000 new cases per year, making it less than one-eighth as common.
The age patterns are also different. Hodgkin’s lymphoma has a distinctive bimodal distribution, meaning it peaks in two separate age groups: young adults between 15 and 35, and adults 55 and older. That first peak makes it one of the more common cancers in teens and young adults. Non-Hodgkin’s lymphoma, on the other hand, becomes steadily more common with age and is diagnosed most often in people over 60.
Symptoms and How They Overlap
Both types share a core set of symptoms: painless swelling of lymph nodes (usually in the neck, armpit, or groin), unexplained fevers, drenching night sweats, and unintentional weight loss. These last three are known collectively as “B symptoms,” and their presence affects staging for both diseases.
One unusual symptom is relatively specific to Hodgkin’s lymphoma: pain in the lymph nodes after drinking alcohol. This is a well-known phenomenon, likely caused by alcohol directly irritating the cancerous cells, which then release inflammatory signals that cause swelling and pain. It doesn’t happen to everyone with Hodgkin’s, but when it does occur, it’s a notable clue.
Because non-Hodgkin’s lymphoma more commonly arises outside the lymph nodes, its symptoms can vary widely depending on where the cancer develops. A lymphoma in the stomach might cause abdominal pain or nausea, while one in the skin might appear as a rash or raised lesion.
Treatment Approaches
Treatment differs significantly between the two, in part because Hodgkin’s lymphoma is generally more responsive to standard chemotherapy and radiation. The backbone chemotherapy regimen for Hodgkin’s lymphoma combines four drugs (commonly abbreviated ABVD). Many patients with early-stage Hodgkin’s receive a few cycles of chemotherapy followed by targeted radiation, and cure rates are high.
Non-Hodgkin’s lymphoma treatment depends heavily on which of the many subtypes a person has and how quickly it’s growing. The most common regimen for aggressive B-cell lymphomas adds an antibody-based drug to a chemotherapy combination (known as R-CHOP), which targets B-cells specifically. Slow-growing subtypes may be monitored without treatment for months or years, a strategy called watchful waiting, until the disease progresses enough to warrant intervention. Other subtypes require entirely different drug combinations.
Both types of lymphoma may also be treated with immunotherapy, targeted therapy, or stem cell transplants in cases that don’t respond to initial treatment or that relapse later.
Outlook and Survival
Hodgkin’s lymphoma is considered one of the most curable cancers, particularly when caught early. Five-year survival rates for localized Hodgkin’s lymphoma exceed 90%, and even advanced cases respond well to treatment in the majority of patients. The predictable spread pattern and sensitivity to chemotherapy both contribute to these outcomes.
Non-Hodgkin’s lymphoma survival varies enormously by subtype. Some indolent forms, while technically not curable, can be managed for decades. Aggressive subtypes like diffuse large B-cell lymphoma are potentially curable with intensive treatment, but outcomes depend on the stage at diagnosis, the patient’s age, and how the cancer responds to initial therapy. The overall five-year survival rate for non-Hodgkin’s lymphoma sits around 74%, but that number blends together dozens of diseases with very different trajectories.